Combination Therapy and Breast Cancer
December 2006 - A new study published in the International Journal of Radiation
Oncology*Biology*Physics has found that radiation therapy and chemotherapy administered concurrently after
lumpectomy helps prevent local reoccurrence of breast cancer. Researchers estimate that more than 213 000 women in the USA will be diagnosed with breast cancer in 2006. For early-stage disease, standard treatment is a lumpectomy (surgical removal of the tumor) followed by radiation therapy to the breast. In addition, chemotherapy is usually recommended for women with invasive disease. Researchers at Yale New Haven Hospital and the Cancer Institute of New Jersey sought to help clarify whether optimal outcomes are obtained by giving chemotherapy after surgery but before radiation therapy, or after completion of the other two forms of treatment.
The study retrospectively analysed data from more than 2000 women over approximately a 25-year period. Of 535 women treated with different combinations, 276 received chemotherapy before radiation therapy, 106 received radiation therapy before chemotherapy, 109 received chemotherapy and radiation therapy concurrently, and 44 received chemotherapy followed by radiation therapy and repeated chemotherapy.
Researchers found a successful outcome for the group as a whole, with 78 per cent survival at the 10-year point. There was no significant difference in the way different combinations affected the general outcome, but the location of tumor reoccurrence did appear to be affected. Only 8 per cent of 109 patients who received concurrent chemotherapy and radiation therapy suffered local relapse in 10 years. However, 13 per cent of 106 women who received radiation therapy before chemotherapy, and 22 per cent of 276 women who had chemotherapy before radiation had a local relapse.
Lead author Bruce G. Haffty, radiation oncologist at Robert Johnson Wood Medical School-UMDNJ and the Cancer Institute of New Jersey said:
"It is important for doctors to test and retest combinations of treatments and how we deliver them to our patients. In this retrospective analysis, by concurrently administering chemotherapy and radiation therapy, there appears to be a benefit to selected patients in terms of local control of the breast cancer. The challenge over the next few years is to identify those patients who would best benefit from this strategy. This can best be accomplished by prospective clinical trials."
A report from the American Cancer Society estimates that 2007 saw over 12 million
new cancer cases and 7.6 million cancer deaths (about 20,000 a day) worldwide. Of these, 5.4 million cases and 2.9
million deaths occurred in economically developed countries, compared to 6.7 million cases and 4.7 million deaths in
A study aimed at improving support services has investigated the lives of
people caring for a partner with cancer and how they negotiate issues surrounding sexuality and intimacy.
New developments in breast cancer imaging, timing of chemotherapy, and vaccine research
may offer innovative non-surgical interventions resulting in significant changes to current screening and treatment
practice and improvements in patient care.
Women with breast cancer who are obese, less educated or have lower household
incomes may be more likely to receive reduced doses of chemotherapy thereby jeopardizing their survival.
New research suggests that significant differences in cancer rates between northern and southern
Europeans may be explained by the anti-cancer effects of olive oil in the diet.
A joint initiative between computer scientists at the University of Edinburgh and cellular biologists at the
Riken Genomic Research Centre in Japan may result in improved drug treatments for breast cancer sufferers that
will also minimize side effects.
A new study concludes that most patients who
undergo gastric cancer staging by lymph node sampling have inadequate assessments that